A small, but important point: David Lane says "trying to get the mutant protein to work again" (like the Swedish company's drug APR-246, PRIMA-1Met, that he talks about)
not "degrades mutant p53."
Kevetrin I hope does the same - gets the mutated p53 to fold into a proper form that then restores some of its lost function.
I likewise was confused at one point, since CTIX's preclinical posters boast of both functions - restoration of function of mutant p53, and degradation of mutant p53.
It's nice to have confirmation from an expert that the desired change to mutant p53 is restoration of function. This makes sense.
Restoring function to mutant p53 should be a big part of the battle against p53 mutant cancer, and could perhaps work as a stand-alone in p53 mutant tumors. It's also possible that Kevetrin combo might be better.
How would anybody know at this point? George seems a little overconfident about this matter, to tell us this over and over again several times every week that Kevetrin will not work very well as monotherapy. Even if it works better in combo, the drug will still be used.
Market Data 
Markets 
AI
